Invesco
AXSM icon

Invesco’s Axsome Therapeutics AXSM Stock Holding History

Invesco’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$219M Buy
1,297,678
+24,184
+2% +$4.18M 0.02% 660
2025
Q4 		$233M Buy
1,273,494
+282,937
+29% +$39.5M 0.02% 619
2025
Q3 		$120M Buy
990,557
+419,008
+73% +$47.2M 0.02% 792
2025
Q2 		$59.7M Sell
571,549
-285,452
-33% -$30.2M 0.01% 989
2025
Q1 		$100M Buy
857,001
+164,537
+24% +$18.7M 0.02% 801
2024
Q4 		$58.6M Buy
692,464
+67,285
+11% +$6.19M 0.01% 980
2024
Q3 		$56.2M Buy
625,179
+67,318
+12% +$5.88M 0.01% 994
2024
Q2 		$44.9M Buy
557,861
+312,208
+127% +$23.1M 0.01% 1057
2024
Q1 		$19.6M Buy
245,653
+199,490
+432% +$16.7M ﹤0.01% 1466
2023
Q4 		$3.67M Sell
46,163
-16,278
-26% -$1.09M ﹤0.01% 2394
2023
Q3 		$4.36M Sell
62,441
-109,131
-64% -$8.16M ﹤0.01% 2280
2023
Q2 		$12.3M Buy
171,572
+111,045
+183% +$8.19M ﹤0.01% 1662
2023
Q1 		$3.73M Sell
60,527
-78,932
-57% -$5.19M ﹤0.01% 2359
2022
Q4 		$10.8M Sell
139,459
-31,591
-18% -$1.89M ﹤0.01% 1795
2022
Q3 		$7.63M Buy
171,050
+158,821
+1,299% +$7.94M ﹤0.01% 1967
2022
Q2 		$469K Sell
12,229
-240
-2% -$7.59K ﹤0.01% 3356
2022
Q1 		$516K Buy
12,469
+56
+0.5% +$1.74K ﹤0.01% 3372
2021
Q4 		$469K Sell
12,413
-1,192
-9% -$43.9K ﹤0.01% 3409
2021
Q3 		$448K Sell
13,605
-150,778
-92% -$5.88M ﹤0.01% 3481
2021
Q2 		$11.1M Buy
164,383
+32,250
+24% +$1.94M ﹤0.01% 1986
2021
Q1 		$7.48M Sell
132,133
-266,959
-67% -$18.8M ﹤0.01% 2142
2020
Q4 		$32.5M Sell
399,092
-28,396
-7% -$2.12M 0.01% 1194
2020
Q3 		$30.5M Sell
427,488
-71,151
-14% -$5.54M 0.01% 1119
2020
Q2 		$41M Sell
498,639
-159,583
-24% -$12.3M 0.01% 1001
2020
Q1 		$38.7M Buy
658,222
+46,863
+8% +$3.82M 0.02% 921
2019
Q4 		$63.2M Sell
611,359
-337,946
-36% -$13.6M 0.02% 896
2019
Q3 		$19.2M Buy
949,305
+141,796
+18% +$3.64M 0.01% 1434
2019
Q2 		$20.8M Sell
807,509
-242,969
-23% -$4.87M 0.01% 1412
2019
Q1 		$14.9M Buy
+1,050,478
New +$9.75M 0.01% 1385

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Invesco's AXSM Position: Q1 2026 in Review

Invesco increased its Axsome Therapeutics (AXSM) stake by 1.9% in Q1 2026, buying an estimated $4.18M and bringing the position to 1,297,678 shares worth $219M. The position accounts for 0.02% of the portfolio, ranked #660.

Invesco first reported a position in AXSM in Q1 2019 and has held it in 29 quarters since. The position peaked at $233M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Invesco held 1,297,678 shares of Axsome Therapeutics worth $219M as of Q1 2026.
  • Invesco bought 24,184 Axsome Therapeutics shares in Q1 2026, an estimated $4.18M.
  • Axsome Therapeutics made up 0.02% of Invesco's portfolio in Q1 2026, its #660 holding.
  • Invesco first reported a position in Axsome Therapeutics in Q1 2019 and has held it in 29 quarters since.
  • Invesco's Axsome Therapeutics position peaked at $233M in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.